No cases of overdose have been reported. In cases of overdose, the patients should be monitored closely and management should be symptomatic and supportive. In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity and local irritation at the injection site. There is no evidence that there is clinical counterpart of this phenomenon. In early clinical trials using daily subcutaneous Leuprorelin Acetate in patients with prostate cancer, doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
